An expedited code stroke protocol is feasible and safe

被引:39
作者
Sattin, Justin A.
Olson, Scott E.
Liu, Lin
Raman, Rema
Lyden, Patrick D.
机构
[1] Univ Calif San Diego, Sch Med, Dept Neurosci, San Diego, CA 92103 USA
[2] Univ Calif San Diego, Sch Med, Dept Family & Prevent Med, San Diego, CA 92103 USA
[3] Vet Adm Med Ctr, Neurol Serv, San Diego, CA USA
关键词
acute care; health resources/utilization; stroke management; thrombolysis;
D O I
10.1161/01.STR.0000249057.44420.4b
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose - Stroke recovery critically depends on timely reperfusion. In July 2003, we set a benchmark onset-to-treatment time of <= 2 hours and instituted an expedited code stroke protocol to accomplish this. We aim to show that the protocol is feasible and safe. Methods - The expedited protocol includes: Benchmark onset-to-treatment within 2 hours; in-person triage of all code stroke patients; unmixed tissue plasminogen activator at the bedside during evaluation; no delays pending coagulation tests, chest x-ray, or stool guiac unless specifically indicated; and no delays pending formal CT interpretation or written consent. Results - Between July 2003 and June 2005, we evaluated 781 patients and treated 103 of 781 (13.2%) with intravenous recombinant tissue plasminogen activator within 3 hours. Of these, we treated 49 of 103 (47.6%) within 2 hours of symptom onset, and 54 of 103 (52.4%) between 2 and 3 hours. The overall risk of symptomatic intracerebral hemorrhage was 4 of 103 (3.9%; 95% CI, 1.1%, 9.6%), and not significantly different from 6.4% (P = 0.42). The hemorrhage risks in those treated within 2 hours of symptom onset and those treated between 2 and 3 hours were not significantly different from each other or from 6.4%. Conclusions - The expedited code stroke protocol is feasible and appears safe. Further study is warranted to confirm its safety and determine whether it results in better clinical outcomes.
引用
收藏
页码:2935 / 2939
页数:5
相关论文
共 17 条
[1]   Guidelines for the early management of patients with ischemic stroke - A scientific statement from the Stroke Council of the American Stroke Association [J].
Adams, HP ;
Adams, RJ ;
Brott, T ;
del Zoppo, GJ ;
Furlan, A ;
Goldstein, LB ;
Grubb, RL ;
Higashida, R ;
Kidwell, C ;
Kwiatkowski, TG ;
Marler, JR ;
Hademenos, GJ .
STROKE, 2003, 34 (04) :1056-1083
[2]   Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility [J].
Barber, PA ;
Zhang, J ;
Demchuk, AM ;
Hill, MD ;
Buchan, AM .
NEUROLOGY, 2001, 56 (08) :1015-1020
[3]   Thrombolysis for acute stroke in routine clinical practice [J].
Bravata, DM ;
Kim, N ;
Concato, J ;
Krumholz, HM ;
Brass, LM .
ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (17) :1994-2001
[4]   URGENT THERAPY FOR STROKE .1. PILOT-STUDY OF TISSUE PLASMINOGEN-ACTIVATOR ADMINISTERED WITHIN 90 MINUTES [J].
BROTT, TG ;
HALEY, EC ;
LEVY, DE ;
BARSAN, W ;
BRODERICK, J ;
SHEPPARD, GL ;
SPILKER, J ;
KONGABLE, GL ;
MASSEY, S ;
REED, R ;
MARLER, JR .
STROKE, 1992, 23 (05) :632-640
[5]   Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset - The ATLANTIS study: A randomized controlled trial [J].
Clark, WM ;
Wissman, S ;
Albers, GW ;
Jhamandas, JH ;
Madden, KP ;
Hamilton, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21) :2019-2026
[6]   The rtPA (Alteplase) 0-to 6-hour acute stroke trial, part A (A0276g) - Results of a double-blind, placebo-controlled, multicenter study [J].
Clark, WM ;
Albers, GW ;
Madden, KP ;
Hamilton, S .
STROKE, 2000, 31 (04) :811-816
[7]   Intravenous tissue-type plasminogen activator therapy for ischemic stroke - Houston experience 1996 to 2000 [J].
Grotta, JC ;
Burgin, WS ;
El-Mitwalli, A ;
Long, M ;
Campbell, M ;
Morgenstern, LB ;
Malkoff, M ;
Alexandrov, AV .
ARCHIVES OF NEUROLOGY, 2001, 58 (12) :2009-2013
[8]   Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) [J].
Hacke, W ;
Kaste, M ;
Fieschi, C ;
von Kummer, R ;
Davalos, A ;
Meier, D ;
Larrue, V ;
Bluhmki, E ;
Davis, S ;
Donnan, G ;
Schneider, D ;
Diez-Tejedor, E ;
Trouillas, P .
LANCET, 1998, 352 (9136) :1245-1251
[9]  
HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017
[10]  
Hacke W, 2004, LANCET, V363, P768